ALKS:NASDAQ
Alkermes Plc
$46.18
arrow_downward
-1.43%(-0.67) 1D
$46.18
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 19, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$46.90
High
$47.26
Low
$45.74
Mkt. cap
7.76B
Avg. vol.
1.77M
Volume
0.00
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
Open
$46.90
High
$47.26
Low
$45.74
Mkt. cap
7.76B
Avg. vol.
1.77M
Volume
0.00
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
News stories
From web sources and news partners
Benzinga
·
45 minutes ago
Stock Market: Will S&P 500 Open Up or Down Today?
FOREX.com
·
1 hour ago
S&P 500 Analysis: SPX Is Going Through One of Its Most Difficult Periods of 2026
Adam Feldman | Substack
·
12 hours ago
Inside the Federal Litigation of Five S&P 500 Giants
BigGo Finance
·
6 hours ago
Chip ETF Eyes Unprecedented Fourth Straight Year of Beating the S&P 500
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitealkermes.com